Continued Fracture Risk Reduction after 12 Months of Romosozumab Followed By Denosumab through 36 Months in the Extension of the Phase 3 Fracture Study in Postmenopausal Women with Osteoporosis

Lewiecki, E Michael; Dinavahi, Rajani V; Lazaretti-Castro, Marise; Ebeling, Peter R; Adachi, J; Miyauchi, Akimitsu; Gielen, Evelien; Milmont, Cassandra E; Libanati, Cesar; Grauer, Andreas

Arthritis & Rheumatology

Continued Fracture Risk Reduction after 12 Months of Romosozumab Followed By Denosumab through 36 Months in the Extension of the Phase 3 Fracture Study in Postmenopausal Women with Osteoporosis

Author:

Lewiecki, E Michael

Dinavahi, Rajani V ; Lazaretti-Castro, Marise ; Ebeling, Peter R ; Adachi, J ; Miyauchi, Akimitsu ; Gielen, Evelien ; Milmont, Cassandra E ; Libanati, Cesar ; Grauer, Andreas

Keywords:

Science & Technology, Life Sciences & Biomedicine, Rheumatology, 3202 Clinical sciences, 3204 Immunology

Arthritis & Rheumatology Continued Fracture Risk Reduction after 12 Months of Romosozumab Followed By Denosumab through 36 Months in the Extension of the Phase 3 Fracture Study in Postmenopausal Women with Osteoporosis

Author:

Keywords:

Arthritis & Rheumatology

Continued Fracture Risk Reduction after 12 Months of Romosozumab Followed By Denosumab through 36 Months in the Extension of the Phase 3 Fracture Study in Postmenopausal Women with Osteoporosis